Atterocor is a drug development company focused on the accelerated development of a novel treatment for adrenal cancer,
a rare endocrine cancer.

Learn More

December 18, 2013
Atterocor Appoints Leading Experts to Clinical Advisory Board Read More >>

October 15, 2013
Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma Read More >>